Matteo Carlino, FRACP, PhD, University of Sydney and Westmead Hospital, Sydney, Australia, discusses overcoming resistance to targeted MAPK inhibition in melanoma. The majority of patients with melanoma will eventually progress on targeted therapy, and both down- and upstream pathways of the MAPK pathway have been shown to be accountable. Pre-clinical models have demonstrated targetability to overcome resistance, however, translating the efficacy to the clinic has, so far, been unsuccessful. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.